An infection-fighting protein that helped human ancestors survive the transition from trees to life on the African plains is now a major genetic risk factor for Alzheimer's disease, the sixth leading cause of death in 21st century America.
The protein, called ApoE4, helped protect early hominids from their pathogen-laden environment but now promotes Alzheimer's and heart disease in modern humans who live about twice as long as their distant ancestors, said Dale Bredesen, a faculty member at the Buck Institute for Research on Aging in Novato.
But after scoring a scientific breakthrough in revealing how the protein contributes to the scourge of Alzheimer's, Bredesen's team is pursuing a potential drug therapy for the degenerative brain disease that afflicts 5.4 million Americans and threatens to spike in prevalence as the population steadily ages.
A drug candidate identified by Bredesen's lab is going into human clinical trials in Australia and could, if all goes well, gain U.S. government approval in three to five years, Bredesen said.
Rammohan Rao, a co-author of the Buck report, said that one of the researchers' goals was “to identify a safe, nontoxic treatment that could be given to anyone who carries the Apo4E gene to prevent the development of Alzheimer's disease.”
An international scientific scramble is on to stem Alzheimer's, which costs more than $200 billion and claims 83,500 lives a year in the United States, including nearly 250 in Sonoma County.
Sonoma's death rate for Alzheimer's disease is 51 per 100,000 population, nearly the same as Marin County, and far higher than Lake (33) and Mendocino (19) and the statewide rate of 29 per 100,000 population, according to a California Department of Public Health report this year.
Even taking into account Sonoma County's unusually large senior population, the region's age-adjusted Alzheimer's death rate of 33.8 percent is still nearly four percentage points higher than the state average.